Immunotherapy

We believe that personalized medicine holds much promise for the future of cancer treatment. Personalized medicine is based on the premise that one size doesn’t fit all, but it employs therapies based on your unique genetic makeup. Instead of treating you with the same protocols as every other cancer patient with your cancer, personalized medicine relies on therapies derived from your own immune cells or that target-specific genes or gene mutations, allowing for therapies tailored to you.

Choose Nebraska Medicine for Immunotherapy Because:

We are Leaders in Immunotherapy Research

The development of immunotherapies is one area of personalized medicine that is taking center stage in cancer research at Nebraska Medicine. Immunotherapy involves a personalized treatment approach that harnesses a patient’s own immune cells to kill cancer, avoiding much of the toxicity of current standard therapies such as chemotherapy.

First in Nebraska to Offer CAR T-cell Therapy

We are one of the first health care organizations in the Midwest to offer the Chimeric Antigen Receptor (CAR) T-cell therapy for people with relapsed diffuse large B-cell non-Hodgkin lymphomas. In one example of personalized medicine, this procedure involves bolstering your own healthy cells to battle your cancer cells.

Growing Cancer Research Resources

The new cancer facility, the Fred & Pamela Buffett Cancer Center at Nebraska Medicine has allowed us to increase the number of research labs now available on campus. The Suzanne and Walter Scott Cancer Research Tower added 98 additional labs dedicated to cancer research and lead to the recruitment of 30 new cancer researchers. Research funding is also expected to grow from the current $60 million of funding annually to more than $100 million over the next few years.